International, Peer Reviewed, Open Access Journal

Journal of Clinical Pharmacology and Therapeutics
(ISSN: 2766-8347)

Submit Manuscript

Journal of Clinical Pharmacology and Therapeutics

Journal of Clinical Pharmacology and Therapeutics is an open access peer reviewed journal which provides latest updates in treatments, advanced procedures, technologies associated within the field of Pharmacology and other related sub-divisions.

Journal Features

Open Access

All the articles will be published under Open Access model.

Peer Review

Our editorial team performs strict peer-review process.

Publication Ethics

The journal follows standard guidelines to maintain transparency.

Submit Manuscript

The journal accepts all original articles, reviews and more.

About the Journal

Journal of Clinical Pharmacology and Therapeutics provide reports on optimal clinical use of various drugs and effects in treatment of patients.

Open Access - Journal of Clinical Pharmacology and Therapeutics

Editorial Board

Sana Irfan Khan - Journal of Clinical Pharmacology and Therapeutics

Sana Irfan Khan

Volunteering as a peer reviewer for submitted manuscripts
United States

Bruno Trimarco - Journal of Clinical Pharmacology and Therapeutics

Bruno Trimarco

Federico II University of Naples (www.unina.it)
Federico II University of Naples, Director of Division of Cardiology, Coronary care unit and Cat Lab Business or sector Medical

Italy

Athanasia Papazafiropoulou - Journal of Clinical Pharmacology and Therapeutics

Athanasia Papazafiropoulou

General Hospital of Piraeus “Tzaneio”, 1st Department of Internal Medicine
Greece

ÖMER ALKAN - Journal of Clinical Pharmacology and Therapeutics

ÖMER ALKAN

Associate professor in the department of econometrics
Turkey

Our Journal Indexed in

Articles

J Clin Pharmacol Ther. 2024;5(3):JCPT-05-1064 | Open Access

Impact of Weight Loss Drugs on Cardiometabolic Parameters: Evaluation of Published Clinical Trials

Jessica M. Van Laren, James M. Backes and Daniel E. Hilleman

Weight loss drugs are indicated for the optimization of health in obese or overweight patients with comorbidities. Weight loss should lead to improvements in lipids, Hgb A1c, and blood pressure. This review addressed the impact of weight loss achieved with drug therapy and the relative magnitude of changes in cardiometabolic parameters observed in randomized placebo-controlled trials. The magnitude of ... Read more

RESEARCH ARTICLE Updated Dec 13, 2024   PDF

J Clin Pharmacol Ther. 2024;5(3):JCPT-05-1063 | Open Access

Inhibition of Pkcβ II Alleviates Renal Ischemia Reperfusion Injury by Suppressing Ferroptosis in Mice

Maodi Gong, Hua Shi, Yikun Wu, Yuangao Xu, Guangyi Hong, Wei Chen and Shuxiong Xu

Renal Ischemia-Reperfusion (I/R) injury can cause renal insufficiency, leading to the need for renal replacement therapy in severe cases, placing a substantial burden on patient recovery and life. Mitigating renal I/R injury is a current research focus. Protein kinase C (PKC) isozymes, with PKCβII as the primary isoform in the kidney, are crucial protein kinases. Ferroptosis ... Read more

RESEARCH ARTICLE Updated Dec 02, 2024   PDF

J Clin Pharmacol Ther. 2024;5(3):JCPT-05-1062 | Open Access

Sodium Zirconium Cyclosilicate-Associated Adverse Events: An Analysis of the FAERS Database

Lin Yimin and Hong Qingxia

Purpose: This study aims to investigate the Adverse Drug Event (ADE) signals associated with potassium ion adhesive sodium cyclozirconate using the United States Food and Drug Administration's Adverse Event Reporting System (FAERS), providing insights for its safe clinical application. Methods: Adverse reactions related to Sodium Zirconium Cyclosilicate (SZC) were retrieved from the FAERS database, covering the period from May 2018 ... Read more

RESEARCH ARTICLE Updated Nov 20, 2024   PDF

J Clin Pharmacol Ther. 2024;5(3):JCPT-05-1061 | Open Access

Phase 1, First-in-Man Clinical Trial and Pharmacokinetics of Psilocin Mucate (L-130)

Sancilio Frederick, Madsen Martin, Dariani Magshoud and Singh Gurpreet

Psilocin mucate (L-130), a stabilized form of psilocin (US Patent 12,102,616), offers a potentially superior option for oral therapeutic formulations compared to psilocybin. A Phase 1, open-label, single-dose pharmacokinetic study was conducted in 10 healthy volunteers to assess the safety, bioavailability, and pharmacokinetic profile of psilocin mucate. The results demonstrated rapid absorption, highly reproducible inter-subject variability and 100% bioavailability. T he compound was well-tolerated, ... Read more

RESEARCH ARTICLE Updated Oct 19, 2024   PDF

J Clin Pharmacol Ther. 2024;5(3):JCPT-05-1060 | Open Access

Safety Profile of Tofacitinib in Autoimmune Rheumatic Disease Patients

George A, Shahul KS, Reji A and Devananda H

Aim and Objective: The study aims to assess the safety profile of Tofacitinib among Autoimmune Rheumatic Disease (ARD) patients in real life, attending the Rheumatology outpatient department of a tertiary care hospital. This short-term prospective observational study was done for 6 months involving 50 ARD patients. Patient's socio-demographic and clinical data were recorded in a predesigned proforma and were analysed for ... Read more

RESEARCH ARTICLE Updated Sep 19, 2024   PDF